The Moderna CEO's Bold Statement That May Mean Bad News for Novavax

Moderna (NASDAQ:MRNA) beat Novavax (NASDAQ:NVAX) to market with a coronavirus vaccine. The U.S. Food and Drug Administration (FDA) authorized Moderna's candidate in December. Novavax expects to report U.S. phase 3 trial data in the coming weeks and complete an Emergency Use Authorization (EUA) request this quarter.